Clinical Trials on Double-Lumen Tube in South Africa

Total 115 results

University of Houston
Michigan State University; Bar-Ilan University, Israel; University of the Free...

Completed

MISC-CBO in Children Affected by HIV/AIDS

HIV Affected Children (Single and/or Double Orphans)

South Africa
Medical Research Council
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Spain, Belgium, France, Netherlands, Austria, United Kingdom, Italy, South Africa, Portugal, Ireland
Kazia Therapeutics Limited

Completed

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Australia
Oncolix, Inc.

Unknown

Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
THERAPIM PTY LTD
Novotech (Australia) Pty Limited

Terminated

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Australia
Queensland Centre for Gynaecological Cancer
The University of Queensland; Cancer Australia Priority-driven Collaborative...

Completed

Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer (OPEN)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Australia
Medical University of South Carolina

Recruiting

Treatment of Eustachian Tube Dysfunction (ETD) and Facial Pain With Combined Acoustic Vibration and Oscillating Expiratory Pressure

Facial Pain | Eustachian Tube Dysfunction

United States
Entellus Medical, Inc.

Completed

XprESS Eustachian Tube Dilation Study

Eustachian Tube Dysfunction

United States
Entellus Medical, Inc.
North American Science Associates Ltd.

Completed

XprESS ET Registry

Eustachian Tube Dysfunction

United States
NHS Greater Glasgow and Clyde

Completed

Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United Kingdom, Australia, New Zealand
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditions

United States
GlaxoSmithKline

Completed

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Neoplasms, Ovarian

United States, Australia, Singapore
University Health Network, Toronto

Completed

A Study of Long-Term Responders on Olaparib (OLALA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Canada, Spain, Australia, Italy, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Fatigue | Anxiety | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC... and other conditions

United States
Novartis Pharmaceuticals

Completed

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Greece, Canada, Finland, Italy, Spain, United Kingdom, France, Denmark, South Africa, Australia, Poland
AltaRex

Unknown

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Fallopian Tube Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Malignant Ovarian Brenner Tumor and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
AltaRex

Unknown

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IA Ovarian Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Ovarian Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Janssen Research & Development, LLC
PharmaMar

Completed

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Poland, United Kingdom, China, Switzerland, Israel, South Africa, Australia, Russian Federation, New Zealand
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Amgen

Completed

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Carcinoma | Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumors | Oncology | Tumors | Metastases | Gynecological Malignancies

Belgium, United States, Australia
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
Hoffmann-La Roche
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Completed

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Korea, Republic of, United States, Italy, Belgium, Australia, France, Austria, China, Denmark, Germany, Greece, Spain, Sweden, Japan, Russian Federation, Turkey, Norway, Brazil, Czechia, Finland, Poland, Israel
Pfizer

Terminated

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Ovarian Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
OncoC4, Inc.
Avance Clinical; OncoC4 AU Pty Ltd

Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditions

Australia
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Ovarian Cancer | Fallopian Tube Cancer

United States
Morphotek

Completed

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Germany
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

Australia, United States, Korea, Republic of, Chile, Belgium, Italy, Spain, Israel, Japan
Precision Therapeutics

Terminated

Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Precision Therapeutics

Terminated

ChemoFx® PRO - A Post-Market Data Collection Study

Cervical Cancer | Uterine Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Peritoneal Cancer

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
MEI Pharma, Inc.

Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (OVATURE)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
Eli Lilly and Company

Completed

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Genital Neoplasms, Female | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Pelvic Neoplasms

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Pain | Neuropathy | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIB Ovarian Cancer | Stage IIIB Primary Peritoneal Cancer | Stage IIIC Fallopian Tube Cancer | Stage IIIC Ovarian Cancer | Stage IIIC Primary... and other conditions

United States
Bayer

Completed

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

Contraception | Neural Tube Defects | Oral Contraceptives (OC)

United States
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
Imunon

Active, not recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Amgen

Terminated

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan

Clinical Trials on Double-Lumen Tube in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations